What happened
ChronoScale Holdings Corporation (NASDAQ: CHRN) said it completed the Ekso Bionics sale and lined up $1 billion in contracted run-rate revenue.
The company said it signed an expanded agreement with an existing AI infrastructure customer and a separate agreement with a new customer.
The 8-K says the sale closed on September 30, 2026.
ChronoScale said the commitments support its plan to build long-term relationships with AI infrastructure customers.
It also said the sale lets it focus operations, management resources and capital allocation on accelerated compute and AI infrastructure.
The company said the expanded relationship and the new customer validate demand and its ability to grow alongside customers.
It also said the commitments increase the scale of its contracted AI infrastructure deployments and strengthen contracted revenues.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| Annualized run-rate revenue | $1 billion | SEC 8-K exhibit 99.1 | |
| Customer agreements | 2 agreements | SEC 8-K exhibit 99.1 | |
| Severance payment | $243,750 | SEC Form 8-K | |
| Preferred stock designated | 5,852 shares | SEC Form 8-K |
Read more: ChronoScale (CHRN) stock analysis and investment case
Why it matters
OptimistFi's case is that ChronoScale must prove a small base can win durable Cloud demand and repeatable cash flow.
This filing helps that case by giving investors a cleaner post-sale benchmark and a larger contracted target to watch.
It also narrows the company to the business line investors will now use to judge execution.
The filing ties the growth story to deployed capacity, not to reported revenue today.
The release says annualized run-rate revenue is an operating metric based on current assumptions.
It is not a forecast for any specific reporting period.
The target also depends on successful and timely deployment, commissioning, power, equipment and access to capital on acceptable terms.
That makes the $1 billion figure a benchmark, not a completed result.
Browse: stock research on every company OptimistFi covers
What's next
The next observable test is calendar Q3 2027, when ChronoScale says annualized run-rate revenue should reach $1 billion.
That outcome would support the post-sale focus and the customer-commitment story.
Meeting the target would also show the contracted pipeline turned into deployed capacity.
Missed deployment, commissioning or financing steps would weaken the case on the filing's own terms.
More from OptimistFi
- CHRN stock: the ChronoScale thesis, its status and the next test to watch
- ON Semiconductor Corporation (NASDAQ: ON) Cuts Its Deal Cost by 19%
- Gevo, Inc. (NASDAQ: GEVO) Turns $70 Million of Credits Into Cash
- Acuity Inc. (NYSE: AYI) Growth Shifts Beyond Lighting
- Stock research on every company OptimistFi covers
- Latest stock research and investment-case updates
- OptimistFi: evidence-first equity research
Sources
- SEC 8-K exhibit 99.1 — Press release announcing the expanded customer agreements and completion of the Ekso Bionics sale.
- SEC Form 8-K — Current report confirming the Ekso Bionics sale closed on September 30, 2026.
Read the full OptimistFi thesis on ChronoScale Holdings Corporation: https://optimistfi.com/stocks/CHRN
See what would break the ChronoScale Holdings Corporation thesis and track it live on the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
The full ChronoScale Holdings Corporation investment case, its status and the next test to watch live on the ChronoScale Holdings Corporation thesis page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
